

BEST AVAILABLE COPY

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

On JULY 30, 2001

TOWNSEND and TOWNSEND and CREW LLP

By: Sharen Donino



PATENT
014058-009050US

RECEIVED
SCE

AUG 09 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SKEIKY *et al.*

Application No.: 09/597,796

Filed: June 20, 2000

For: FUSION PROTEINS OF
MYCOBACTERIUM TUBERCULOSIS

Examiner: Swartz, Rodney P.

Art Unit: 1645

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Box SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Action mailed May 31, 2001, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

In the Specification:

Please replace the paragraph beginning at page 4, line 15, with the following:

B1

--Figure 4 shows the nucleotide (SEQ ID NO:1) and amino acid (SEQ ID NO:2) sequence of Ra35 (N-terminal portion of MTB32A).--



DATE: